Trial Profile

Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary) ; Tocilizumab (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions; Therapeutic Use
Acronyms READ-4

Most Recent Events

11 Aug 2023 Planned End Date changed from 1 Oct 2018 to 5 Oct 2016.
11 Aug 2023 Planned primary completion date changed from 1 Feb 2018 to 5 Oct 2016.
11 Aug 2023 Planned initiation date changed from 1 Dec 2017 to 1 Oct 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com